You are here

P&T News

January 12

Pharmacists call shortage of small-volume parenteral solutions "severe"
First PARP inhibitor to receive FDA approval for use beyond ovarian cancer

January 11

CMS issues guidance allowing states to propose programs
Low levels of the mineral are common among women
Society for Healthcare Epidemiology of America provides guidance
Lipocine defends drug’s safety and efficacy

January 9

DOJ is investigating drug-makers’ financial support of patient-assistance charities
The treatment is being jointly developed by Eisai and Merck
Researchers collaborated to study the effect of advances in screening and treatment
Replacing daily pills with a weekly regimen could help patients adhere to therapy
The drug also has fast-track, orphan drug, and rare pediatric disease status

January 8

Medication used as monotherapy for high-risk cases
Getting the shot every year was about twice as effective
Drug previously limited to those with solid tumors

January 4

So-called “association plans” would be cheaper but cover less
The industry expected the gene therapy for a rare form of blindness to cost $1 million
Atcell is derived from adipose and meant for autologous use

January 2

But average returns on research and development have fallen
The mechanism of action is not fully understood, but additional trials are indicated

December 28

Valsartan was first FDA-approved in 2001 as Diovan tablets

Pages